Affymax, Inc. is a biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2006-12-15. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The firm has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.
Follow-Up Questions
Affymax Inc의 CEO는 누구입니까?
Mr. Jonathan Couchman은 2014부터 회사에 합류한 Affymax Inc의 President입니다.
AFFY 주식의 가격 성능은 어떻습니까?
AFFY의 현재 가격은 $0.0008이며, 전 거래일에 decreased 0% 하였습니다.
